威尔吉斯公司将以1.05亿美元的股票收购Neuritek Therapeutics, 以促进PTSD治疗. Wellgistics to acquire Neuritek Therapeutics for $105M in stock to advance PTSD treatment.

威尔吉斯健康公司签署了一份无约束意向书, 探索收购Neuritek Therapeutics, 一家神经科学公司开发一流口服PTSD治疗以FAAH1酶为目标. 全股价值1.05亿美元的交易. Wellgistics Health Inc. has signed a non-binding letter of intent to explore acquiring Neuritek Therapeutics, a neuroscience company developing a first-in-class oral PTSD treatment targeting the FAAH1 enzyme, in an all-stock deal valued at $105 million. 这次潜在收购旨在将Neuritek的研究与Wellgistics人工智能药房分销和患者访问平台整合起来, 以提高药物开发协调性并创造新的收入机会. The potential acquisition aims to integrate Neuritek’s research with Wellgistics’ AI-powered pharmacy distribution and patient access platform to enhance drug development alignment and create new revenue opportunities. 交易仍需经过尽职调查,最终协议和批准,没有完成的保证. The transaction remains subject to due diligence, final agreements, and approvals, with no guarantee of completion. 威尔吉斯学也在考虑其他医疗保健和生命科学领域的机会. Wellgistics is also considering other healthcare and life sciences opportunities.